| Project/Area Number |
20590113
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Kobe Pharmaceutical University |
|---|
Principal Investigator |
SUHARA Yoshitomo Kobe Pharmaceutical University, 環境科学研究室, 准教授 (30297171)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 脂溶性ビタミン / 再生医療 / 脳神経変性疾患 / 治療薬 / 脂溶性リガンド / ゲノム創薬 / 有機合成化学 / コンビナトリアルケミストリー / ビタミンK / 分化誘導作用 / 脳神経変性疾患治療 / 合成化学 / コンビナトリアル合成 / イソプレノイド |
|---|
| Research Abstract |
We focused on vitamin K analogues among fat-soluble vitamins to explore therapeutic agents for degenerative disease of brain. It has been clarified that menaquinone-4 (MK-4), one of the vitamin K homologues, is biosynthesized in a living body and accumulated to the various tissues. MK-4 also protected oligodendrocyte precursors and immature fetal cortical neurons from oxidative injury, independent of the vitamin K-dependent γ-carboxylative reaction. Therefore, MK-4 should play an important role for a living body, especially in brain. On the basis of these findings, we evaluated the biological action of vitamin K homologues with chemical techniques using fluorescent labeled and deuterated labeled analogues. Furthermore, we also synthesized new vitamin K analogues and evaluated biological activities such as their differentiation-inducing activity from stem cells to neuron and gene transcription through the steroid and xenobiotic receptor (SXR).
|
